KALA Bio Signs LOI to Acquire $12.7M-Revenue Telehealth Platform for $15M
KALA is trading near its 52-week low of $0.431 (9.9% above the low).
Summary
KALA Bio signed a non-binding LOI to acquire a 50-state telehealth platform with $12.7M TTM revenue and $48M in sales since inception for approximately $15M in cash and stock. The target is cash-flow positive and serves over 90,000 clients in GLP-1 weight management, hormone health, and longevity. This would be a transformative acquisition for KALA, whose market cap is under $9M and cash is under $0.1M, adding a revenue-generating business and a direct-to-consumer channel for its Virotek genetic testing. The deal is subject to due diligence, definitive agreements, and stockholder approval, with closing targeted for late 2026 or early 2027. The LOI follows KALA's recent Nasdaq delisting notice and pending reverse split vote, making this acquisition a potential lifeline for the company's listing and business viability.
At the time of this announcement, KALA was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.43 to $974.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.